Theralizumab Biosimilar - Research Grade

Product Specifications

Background

Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system’s T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family) . It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006.

Product Name Alternative

TGN1412, CD28-SuperMAB, TAB08

UniProt

P10747

Reactivity

Human

Target

CD28

Isotype

IgG4

Sequence

https://www.imgt.org/mAb-DB/

Applications

Functional Assays

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

5mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE

Buffer

ICH3002

References & Citations

Huang et al. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. Journal of Translational Medicine